Publications
Detailed Information
한국형 DUR의 효과적 추진전략 : Strategy for establishing an effective Korean drug utilization review system
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최남경 | - |
dc.contributor.author | 박병주 | - |
dc.date.accessioned | 2012-06-25T02:44:40Z | - |
dc.date.available | 2012-06-25T02:44:40Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION; Vol.53 12; 1130-1138 | ko_KR |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77371 | - |
dc.description.abstract | Drug utilization review (DUR) system has been defined as "structured, ongoing initiatives that interpret patterns of drug use in relation to predetermined criteria, and attempt to prevent or minimize inappropriate prescribing." This paper introduces the concept, purpose, and effective application of OUR in Korea. OUR can be classified as retrospective OUR, prospective OUR, and concurrent OUR based on the time direction of applying OUR. OUR can also be classified as quantitative DUR defined by retrospective OUR using databases including previously prescribed medicines, and qualitative DUR defined by OUR reflecting patient`s clinical condition. We described the history of developing OUR in the United States and the Europe. Finally current status of DUR in Korea is described and the strategy of future settlement of DUR system in Korea is suggested. | ko_KR |
dc.language.iso | ko | ko_KR |
dc.publisher | KOREAN MEDICAL ASSOC | ko_KR |
dc.subject | Drug utilization review system | ko_KR |
dc.subject | Korea | ko_KR |
dc.subject | Drug safety | ko_KR |
dc.title | 한국형 DUR의 효과적 추진전략 | ko_KR |
dc.title.alternative | Strategy for establishing an effective Korean drug utilization review system | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | Choi, Nam-Kyong | - |
dc.contributor.AlternativeAuthor | Park, Byung-Joo | - |
dc.identifier.doi | 10.5124/jkma.2010.53.12.1130 | - |
dc.citation.journaltitle | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.description.citedreference | KIM DS, 2010, HIRA POLICY TREND, V4, P14 | - |
dc.description.citedreference | PARK JY, 2010, HIRA POLICY TREND, V4, P23 | - |
dc.description.citedreference | *INT SOC PHARM, 2010, EUR DRUG UT RES GROU | - |
dc.description.citedreference | CHOI BC, 2009, HIRA POLICY TREND, V3, P11 | - |
dc.description.citedreference | SHIN KS, 2009, HIRA POLICY TREND, V3, P22 | - |
dc.description.citedreference | PARK BJ, 2008, J PHARMACOEPIDEMIOL, V1, P13 | - |
dc.description.citedreference | Yeom JH, 2005, ANN PHARMACOTHER, V39, P1918, DOI 10.1345/aph.1E674 | - |
dc.description.citedreference | HENNESSY S, 2005, PHARMACOEPIDEM DR S, P833 | - |
dc.description.citedreference | PARK BJ, 1999, KOREAN J CLIN PHARM, V7, P3 | - |
dc.description.citedreference | ERWIN WG, 1991, CLIN PHARMACOL THER, V50, P596 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.